You are here
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
Phone: (919) 354-1066
Email: kwb10@duke.edu
Phone: (919) 406-4367
Email: kwb10@duke.edu
DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKDpatients. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.
* Information listed above is at the time of submission. *